Iloprost Pharmamentum (Iloprost Trometamol)

Iloprost, the active ingredient in Iloprost Pharmamentum, is a prostacyclin analog presented as a solution for injection for intravenous use. It treats pulmonary arterial hypertension and digital ulcers associated with systemic sclerosis.\n\nGNH India supplies Iloprost Pharmamentum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost acts on the prostacyclin pathway to manage severe pulmonary vascular disease and related complications.\n\nPulmonary arterial hypertension: improves exercise capacity and lowers pulmonary arterial pressure.\nDigital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation.\nPulmonary hypertension (including chronic thromboembolic forms): reduces pulmonary vascular resistance and may improve symptoms.

Iloprost may cause a range of adverse reactions, most of which are dose‑related and transient.\n\nCommon Side Effects:\n- Headache: mild to moderate, often early in therapy.\n- Flushing: warm sensation, usually transient.\n- Nausea or vomiting: gastrointestinal upset.\n- Jaw pain or toothache: mimics angina‑like discomfort.\n- Diarrhea: loose stools, generally self‑limiting.\n- Hypotension: mild drop in blood pressure, especially with rapid infusion.\n\nSerious or Rare Side Effects:\n- Severe hypotension or shock: marked blood pressure fall requiring medical intervention.\n- Bleeding complications: increased risk when combined with anticoagulants.\n- Pulmonary edema: fluid accumulation in lungs, rare but serious.\n- Thrombocytopenia: low platelet count, may predispose to bleeding.\n- Arrhythmias: abnormal heart rhythms, especially in patients with cardiac disease.\n- Anaphylactic reaction: rare hypersensitivity requiring immediate treatment.

Before initiating Iloprost, clinicians should assess patient‑specific risk factors and monitor for potential complications.\n\nMonitor blood pressure: watch for hypotension during and after infusion.\nAssess bleeding risk: avoid in patients with active hemorrhage or uncontrolled coagulopathy.\nUse cautiously in renal impairment: dose adjustment may be required.\nAvoid in recent myocardial infarction: risk of further ischemia.\nPregnancy and lactation: safety not established; weigh benefits against potential risks.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost can interact with several drug classes, altering its safety profile or efficacy.\n\nMajor Interactions (Avoid):\n- Concomitant prostacyclin analogs: additive vasodilation may cause severe hypotension.\n- Potent vasodilators (e.g., nitroglycerin): risk of profound blood pressure drop.\n- Anticoagulants (e.g., warfarin, heparin): increased bleeding tendency.\n\nModerate Interactions (Monitor Closely):\n- CYP450 inhibitors (e.g., erythromycin): may modestly raise Iloprost exposure.\n- CYP450 inducers (e.g., rifampicin): may reduce therapeutic effect.\n- Diuretics: may enhance hypotensive effect, requiring blood pressure monitoring.